- Home
- VYNE vs SNOA Comparison
VYNE vs SNOA Comparison
Compare VYNE & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- SNOA
- Stock Information
- Founded
- VYNE 2003
- SNOA 1999
- Country
- VYNE United States
- SNOA United States
- Employees
- VYNE N/A
- SNOA N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- SNOA Health Care
- Exchange
- VYNE Nasdaq
- SNOA Nasdaq
- Market Cap
- VYNE 7.9M
- SNOA 7.5M
- IPO Year
- VYNE 2018
- SNOA 2007
- Fundamental
- Price
- VYNE $0.30
- SNOA $4.24
- Analyst Decision
- VYNE Buy
- SNOA
- Analyst Count
- VYNE 2
- SNOA 0
- Target Price
- VYNE $8.00
- SNOA N/A
- AVG Volume (30 Days)
- VYNE 1.7M
- SNOA 76.2K
- Earning Date
- VYNE 11-06-2025
- SNOA 11-06-2025
- Dividend Yield
- VYNE N/A
- SNOA N/A
- EPS Growth
- VYNE N/A
- SNOA N/A
- EPS
- VYNE N/A
- SNOA N/A
- Revenue
- VYNE $476,000.00
- SNOA $14,912,000.00
- Revenue This Year
- VYNE N/A
- SNOA $23.00
- Revenue Next Year
- VYNE N/A
- SNOA $24.59
- P/E Ratio
- VYNE N/A
- SNOA N/A
- Revenue Growth
- VYNE N/A
- SNOA 17.43
- 52 Week Low
- VYNE $0.28
- SNOA $1.75
- 52 Week High
- VYNE $4.30
- SNOA $6.92
- Technical
- Relative Strength Index (RSI)
- VYNE 31.65
- SNOA 48.08
- Support Level
- VYNE $0.30
- SNOA $3.80
- Resistance Level
- VYNE $0.33
- SNOA $4.68
- Average True Range (ATR)
- VYNE 0.02
- SNOA 0.21
- MACD
- VYNE 0.02
- SNOA -0.10
- Stochastic Oscillator
- VYNE 39.80
- SNOA 47.42
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.